Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 2/20 | 0.56 |
| ▸ | AKR1C3 | P42330 | 6/20 | 0.51 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.51 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | CDC42 | P60953 | 1/20 | 0.51 |
| ▸ | RAC1 | P63000 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4284739 | 0.75 | CYP26A1 (0.65) | ALOX5AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL306953 | 0.74 | ABCB11 (0.54) | ALOX5AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL10333407 | 0.72 | ABCB11 (0.51) | ALOX5AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL9797170 | 0.71 | ALOX5 (1.00) | ALOX5AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL13340952 | 0.71 | PTGS2 (0.66) | ALOX5AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL4280477 | 0.71 | GABBR2 (0.49) | ALOX5CYP1A2LMNAMAPTCYP2C9 | |
| SCHEMBL11778937 | 0.71 | AKR1C3 (0.71) | ALOX5AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL22217506 | 0.71 | PTGS2 (0.69) | ALOX5AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL20887115 | 0.71 | PTGS2 (0.69) | ALOX5AKR1C3AKR1C2PTGS2PTGS1 | |
| SCHEMBL11782635 | 0.71 | AKR1C3 (0.56) | ALOX5AKR1C3AKR1C2PTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7102008-B2 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | claimed |
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | claimed |
| WO-2004012663-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | claimed |
| US-7102008-B2 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-09-05 | — | — | US | disclosed |
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-01 | — | — | US | disclosed |
| WO-2004012663-A2 | HYDANTOIN DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063698-A1 | Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme | MMP9, ADAM17, MMP3 | ALOX5 2741/4885AKR1C3 2969/4885AKR1C2 3162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.